Product
Sacubitril + Valsartan
Aliases
placebo to sacubitril/valsartan, Sacubitril and Valsartan-Reference product, Sacubitril and Valsartan-Test product
Name
ENTRESTO
INN Name
Sacubitril and Valsartan
FDA Approved
Yes
3 clinical trials
3 organizations
3 indications
1 document
Indication
Healthy SubjectsIndication
Congestive Heart FailureIndication
Healthy Control ParticipantsClinical trial
A Bioequivalence Study of Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets in Healthy Thai Volunteers Under Fasting ConditionStatus: Not yet recruiting, Estimated PCD: 2024-06-22
Clinical trial
Controlled Trial on the Short-term Effects of Sacubitril/Valsartan Therapy on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Patients With NYHA II-III Heart Failure and Reduced Systolic Function Using 11C-acetate Positron Emission Tomography and EchocardiographyStatus: Completed, Estimated PCD: 2022-03-23
Clinical trial
A Bioequivalence Study of Two Formulations of Sacubitril/Valsartan 24 mg/26 mg Film-coated Tablets in Healthy Thai Subjects Under Fasting ConditionsStatus: Not yet recruiting, Estimated PCD: 2024-03-01
Organization
Aphena Pharma Solutions - Tennessee, LLC Document
DailyMed Label: ENTRESTOOrganization
Novartis Pharmaceuticals CorporationOrganization
Aphena Pharma Solutions - Tennessee, LLC